Drug Trial Radar · NCT06717438
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Actual
Start
May 13, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- Dec 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the efficacy, safety, and tolerability of BPN14770 in participants aged 9 to 45 years with JS.
Conditions
- Jordan's Syndrome
- PPP2R5D Neurodevelopmental Disorder
Interventions
BPN14770Drug
Capsules for oral administration
PlaceboDrug
Capsules for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline at Week 24 in Numerical Rating Scale Within the Domain of Language/CommunicationTime frame: Baseline, Week 24
- Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 up to Week 96
- Discontinuation-emergent Signs and Symptoms (DESS) Questionnaire ScoreTime frame: Week 98
- Number of Participants with SeizuresTime frame: Up to Week 96
- Number of Participants at Suicidality RiskTime frame: Up to Week 96
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Rush University Medical Center
Chicago, Illinois
Boston Children's Hospital
Boston, Massachusetts
Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.